Drug intelligence / Profile preview

GD-25

Development stage: Preclinical
Lead developer: Gudui BioPharma
Modality: Small Molecules

Overview

GD-25 is a preclinical small molecule inhibitor developed by Gudui BioPharma. It specifically targets the voltage-gated sodium channel Nav 1.8 (encoded by the SCN10A gene). Nav 1.8 is primarily expressed in peripheral sensory neurons (nociceptors) and plays a critical role in the transmission of pain signals. By selectively blocking Nav 1.8, GD-25 aims to provide potent analgesia for acute pain while minimizing the central nervous system and cardiovascular side effects often associated with non-selective sodium channel blockers or opioids.

Targets

SCN10A (Sodium channel protein type X alpha subunit)

Beyond the preview

Go deeper on GD-25.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on GD-25.

Explore the full profile